Acceptance and Commitment Therapy for Insomnia - Trial NCT06336551

Timeline & Enrollment

Primary Outcome

Insomnia severity

Summary

Insomnia is a common sleep problem that impacts both physical and mental health. Acceptance
 and Commitment Therapy for Insomnia (ACT-I) is proposed as a promising new treatment for
 insomnia. However, its effectiveness without overlapping behavioral components of the current
 standard treatment, cognitive behavioral therapy, remains largely unknown.
 
 The main goal of this clinical trial is to test the efficacy of stand-alone ACT-I in adults
 with insomnia, compared to a waitlist control group. The second goal is to explore the
 potential working mechanisms of ACT-I, using network intervention analysis.
 
 Adults with insomnia will be randomized to an ACT-I or waitlist group. Both the ACT-I
 treatment and waiting period span 7 weeks. Assessments take place at baseline (pre), after 4
 weeks (mid), and after 8 weeks (post), followed by a 3- and 6-month follow-up for the ACT-I
 group.
 
 The main questions this RCT aims to answer are:
 
 - Is ACT-I superior to a waitlist control group in improving insomnia severity (primary
 outcome) in addition to sleep diary measures, anxiety, depression, general mental
 health, and sleep-related quality of life (secondary outcomes)?
 
 - How do networks of insomnia symptoms or potential treatment processes (i.e.,
 psychological (in)flexibility, sleep-related arousal, dysfunctional cognitions, and
 sleep-related safety behaviors) develop during and following ACT-I?

ICD-10 Classifications